Nolte Alexander's Form 4 filing
Syndax Pharmaceuticals Inc (SNDX) · filed Feb 3, 2022
- Accession no.
- 0001562180-22-001077
- Filed
- Feb 3, 2022
- Trade date
- Jan 31-Feb 2, 2022
- Filing delay
- 3 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $16.1K. It was filed 3 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Nolte AlexanderCIK 0001891979 | Officer (Chief Accounting Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jan 31, 2022 | Common Stock | JOtherAcquired | +968 | $12.39 | +$11,993.52 | 968 | Direct | |
| Feb 1, 2022 | Common Stock | SSaleDisposed | −968 | $16.65 | −$16,117.2 | 0 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 2, 2022 | Common Stock | AGrant or awardAcquired | +30,000 | $15.79 | +$473,700 | 30,000 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.